14 results about "Haematological malignancy" patented technology

The present disclosure relates to CD19 / 22 CAR T-cell products and methods for treating high risk or relapsed CD19+ or CD22+ haematological malignancies.

The invention belongs to the technical field of biological medicines, and particularly relates to a culture reagent composition and a culture method for a malignant tumor organ of a blood system. The invention firstly provides a reagent composition for culturing a hematological malignant tumor organoid, wherein the hematological malignant tumor comprises acute lymphoblastic leukemia or acute myeloid leukemia; the reagent composition comprises a bone marrow microenvironment simulation matrix reagent and a specific culture medium. By adopting the reagent composition provided by the invention, the hematoma organs can be efficiently cultured, and the survival rate is high. And compared with Matrigel matrigel commonly used in the field, the bone marrow microenvironment simulation matrix component adopted by the invention enables phenotypic differentiation of hematoma organs to be more accurate.

The present application relates to a kind of heterocyclic compounds and its application, the structure of the heterocyclic compound is as shown in formula (I) or formula (II), it is proved by experiment that the heterocyclic compounds can be degraded CK1 alpha by molecular glue mechanism, thereby affecting p53 pathway, Wnt / β-catenin pathway and ATM pathway etc., can be used for preventing or treating the disease caused by CK1 alpha abnormal high expression, can be used for preparing the drug for treating hematological malignancies and solid tumor, especially for preparing the drug for treating acute myeloid leukemia.

Novel nucleic acid compositions, vectors, modified cells and pharmaceutical compositions are provided that are useful for treating or preventing a relapse of a haematological malignancy after allogeneic stem cell transplantation (allo-SCT) in a HLA-A*0201 positive human subject. Corresponding methods and uses are also provided.

Extranodal natural killer / T-cell lymphoma (ENKTCL) is an aggressive haematological malignancy. The treatment of ENKTCL is dependent on the extent of the tumor. However the use of L-asparaginase-containing regimens obtained impressive outcomes as induction or salvage treatment for ENKTCL. Although more than 70% of early-stage patients can achieve long-term survival, patients with advanced-stage disease had extremely poor prognosis even after asparaginase-based chemotherapy regimens. There is thus a medical need for improving the treatment of ENKTCL with L-asparaginase. Now the inventors demonstrate the interest of the use of L-asparaginase in combination with a ferroptosis inducer for the treatment of ENKTCL. In particular, combination of APR-246 and Erwinase R has synergistic effects in KHYG-1 cells. The present invention thus relates to the use of a L-asparaginase in combination with a ferroptosis inducer for the treatment of ENKTCL.

In certain embodiments, this disclosure relates to method of treating and diagnosing cancer by administering a Bcl-2 inhibitor optionally in combination with a mitochondrial complex II inhibitor. In certain embodiments, a subject is diagnosed with, exhibiting symptoms of, or at risk of cancer wherein the cancer is a hematological malignancy such as multiple myeloma, leukemia, or lymphoma.

The present disclosure relates to methods for treating blood transfusion-dependent hematological malignancy patients with oxygen reduced blood.

The invention discloses a triptolide peptide conjugate as well as a pharmaceutical composition and application thereof, and successfully designs and synthesizes the triptolide peptide conjugate which shows remarkable tumor cell proliferation inhibition activity. K-1 shows an excellent inhibition effect on a specific solid tumor cell strain; K-1 has particularly outstanding inhibition activity on a hepatoma cell strain HuH-7, a pancreatic cancer cell strain MIA PaCa-2 and a gastric cancer cell strain HGC-27; the compound shows broad-spectrum and high-efficiency anti-tumor characteristics as shown in the formula K-1, K-2 and K-3, and shows excellent inhibitory activity on a hepatoma cell line HepG2, an acute myelogenous leukemia cell line KG-1, a multiple myeloma cell line RPMI-8226 and a pancreatic cancer cell line MIA PaCa-2. The result not only proves the effectiveness of the K-3 on various solid tumors, but also highlights the strong inhibition effect of the K-3 on malignant tumors of a blood system, and shows the prospect of the K-3 as a broad-spectrum anti-tumor candidate drug. And a powerful guarantee is provided for subsequent deep development of potential antitumor candidate drug molecules and final realization of clinical application transformation.

The application discloses a D-A-D type organic small molecule, nanoparticles containing the same, and a preparation method and application thereof. The D-A-D type organic small molecule and the nanoparticles thereof are particularly suitable for precise photothermal treatment and real-time imaging guidance of hematological malignancies such as leukemia, lymphoma and multiple myeloma. The D-A-D type organic small molecule constructs a D-A-D type conjugated structure, realizes near-infrared absorption red shift to 685 nm through enhancing intramolecular charge transfer (ICT) effect, and promotes non-radiative transition by using high excited state reorganization energy (lambda=1.29eV), with a photothermal conversion efficiency of more than 35%. The small molecule does not contain metal and halogen, has a molecular weight of about 878 Da, and has good biocompatibility and metabolic potential. The small molecule is self-assembled into nanoparticles with a particle size of about 130 nm, and has good colloidal stability and passive targeting ability. Meanwhile, the high molar absorption coefficient and high-efficiency photothermal conversion characteristics of the small molecule endow the small molecule with strong photoacoustic imaging capability, and the small molecule can be used for real-time monitoring of drug distribution and realization of 'diagnosis and treatment integration'.

This invention discloses a predictive model for assessing the risk of severe cytokine release syndrome (SCR) in patients with hematologic malignancies after CAR-T cell therapy. The model includes a nomogram and a prognostic risk scoring formula to assess the risk of SCR after CAR-T cell infusion. The biomarkers are the peripheral blood cytokine concentrations during 24-48 hours after CAR-T cell infusion, including five cytokines: CX3CL1, GZMB, IL4, IL6, and PDGFAA. The nomogram in this invention is the first predictive model established applicable to assessing the risk of SCR in patients with leukemia, lymphoma, and multiple myeloma undergoing CAR-T cell therapy. The model is simple, intuitive, and easy to implement, effectively helping clinicians assess the risk of SCR after CAR-T cell therapy, thus providing theoretical guidance for patient monitoring and treatment.

Novel nucleic acid sequences, vectors, modified cells, peptides and pharmaceutical compositions are provided that are useful in the treatment of human subjects having a ΔNPM1 positive haematological malignancy. Corresponding methods and uses are also provided.

Provided herein are novel nucleic acid compositions, vector systems, engineered cells, and pharmaceutical compositions that encode or express T cell receptor components against cancer-associated antigens (e.g., preferentially expressed melanoma antigen (PRAME) and CCCTC-binding factor (CTCFL)). These novel compositions may be used to enhance immune responses in subjects diagnosed with a PRAME-associated disease or condition, such as a hematological malignancy or solid tumor, or a CTCFL-associated disease or condition. Related methods for treating such subjects are also provided herein.

The application discloses YY20394 and ABT199 combination in the application of preparing a drug for treating acute myeloid leukemia. The application firstly finds that YY20394 and ABT199 have a synergistic effect on the treatment of acute myeloid leukemia, and the treatment effect of acute myeloid leukemia with MCL-1 overexpression can be significantly improved by combining YY20394 and ABT199. The application provides a brand-new treatment scheme for the technical field of blood system malignant tumor treatment, and has important scientific significance and clinical application value.